Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia

被引：30
|
作者：
Khalili, Hossein [1 ]
Shojaei, Lida [2 ]
Mohammadi, Mostafa [3 ]
Beigmohammadi, Mohammad-Taghi [3 ]
Abdollahi, Alireza [4 ]
Doomanlou, Mahsa [5 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Kermanshah Univ Med Sci, Fac Pharm, Dept Clin Pharm, Kermanshah, Iran
[3] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Intens Care Unit, Tehran, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Pathol, Tehran, Iran
[5] Univ Tehran Med Sci, Cent Lab, Imam Hosp Complex, Tehran, Iran
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 09期
关键词：
Acinetobacter; ampicillin-sulbactam; colistin; pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; AMPICILLIN-SULBACTAM; INTRAVENOUS COLISTIN; RISK-FACTORS; POLYMYXIN-B; MORTALITY; SURVEILLANCE; INFECTIONS;
D O I：
10.2217/cer-2018-0037
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively. Conclusion: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.
引用
收藏
页码：901 / 911
页数：11
相关论文
共 50 条
  • [41] Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli
    Kim, Hye-Rim
    Eom, Yong-Bin
    ANTIBIOTICS-BASEL, 2021, 10 (02): : 1 - 13
  • [42] Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
    Oliveira, M. S.
    Prado, G. V. B.
    Costa, S. F.
    Grinbaum, R. S.
    Levin, A. S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (06) : 1369 - 1375
  • [43] Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
    Zhang, Helen L.
    Cressman, Leigh
    Lautenbach, Ebbing
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 27 : 299 - 302
  • [44] Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
    Nutman, Amir
    Lellouche, Jonathan
    Temkin, Elizabeth
    Daikos, George
    Skiada, Anna
    Durante-Mangoni, Emanuele
    Dishon-Benattar, Yael
    Bitterman, Roni
    Yahav, Dafna
    Daitch, Vered
    Bernardo, Mariano
    Iossa, Domenico
    Zusman, Oren
    Friberg, Lena E.
    Mouton, Johan W.
    Theuretzbacher, Ursula
    Leibovici, Leonard
    Paul, Mical
    Carmeli, Yehuda
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (09) : 1185 - 1191
  • [45] Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms
    Geladari, Anastasia
    Simitsopoulou, Maria
    Antachopoulos, Charalampos
    Roilides, Emmanuel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (03)
  • [46] Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model
    Cai, Yun
    Yang, Deqing
    Wang, Jin
    Wang, Rui
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (02) : 456 - 461
  • [47] TREATMENT OF GONORRHEA WITH AMPICILLIN-SULBACTAM - REPLY
    BADDOUR, LM
    SEXUALLY TRANSMITTED DISEASES, 1993, 20 (04) : 238 - 239
  • [48] TREATMENT OF GONORRHEA WITH AMPICILLIN-SULBACTAM - RESPONSE
    SCHACTER, J
    SEXUALLY TRANSMITTED DISEASES, 1993, 20 (04) : 239 - 239
  • [49] In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
    Pfaller, Michael A.
    Huband, Michael D.
    Mendes, Rodrigo E.
    Flamm, Robert K.
    Castanheira, Mariana
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (02) : 144 - 150
  • [50] Evaluation of the Efficacy of Colistin/Sulbactam Combination on Carbapenem-Resistant Acinetobacter baumannii Strains
    Cetinkol, Yeliz
    Telli, Murat
    Altuncekic Yildirim, Arzu
    Calgin, Mustafa Kerem
    MIKROBIYOLOJI BULTENI, 2016, 50 (03): : 460 - 465
12345